BALTIMORE, April 4, 2017 /PRNewswire/ -- Intralytix, Inc. announced today that the Company is partnering with BioPhage TherapeuticsLimited to develop and commercialize topical bacteriophage treatments of human wounds infected or colonized with S. aureus.
"Treatment of bacteria-infected wounds is one the most critical problems in modern medicine. Infected
"We view this partnership as an important step in developing phage-based products for managing wounds infected with S. aureus," stated John Woloszyn, Intralytix's CEO. "Working with BioPhage Therapeutics, we aim to rapidly bring our bacteriophage technology to the market, and to offer a natural, safe, and effective antimicrobial approach to millions of people suffering from infected, hard-to-heal wounds," Mr. Woloszyn added.
Intralytix, Inc. is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health, human therapeutics, and dietary supplements and probiotics. The Company has the world's largest portfolio of FDA-approved phage preparations for food safety applications and is involved in the development of several additional products for human therapeutic, veterinary medicine, probiotic, and other applications.
BioPhage Therapeutics Limited is a British company with strong skills in the clinical development, registration, and marketing of therapeutic drug products. "The partnership with Intralytix is ideal," stated Robert Jackson, Chairman of BioPhage. "We can build upon Intralytix's strength in bacteriophage science by formulating their phage into a drug product that will be in clinical trials at leading UK teaching hospitals by the end of the year."
For more information, contact:
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intralytix-inc-and-biophage-therapeutics-limited-partner-to-develop-topical-bacteriophage-treatments-of-human-wounds-infected-with-s-aureus-300434608.html
SOURCE Intralytix, Inc.
Subscribe to our Free Newsletters!
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...View All